Navigation Links
New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering From Painful Peripheral Neuropathy
Date:1/28/2011

and osteoarthritic pain.  Also in the current study, the mean percentage of days on treatment with tapentadol ER that patients experienced nausea, vomiting, and constipation, respectively, was relatively low in both the open-label (8.8, 2.2 and 5.4 percent) and, particularly, in the double-blind (2.9, 1.0 and 1.9 percent) phases.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) and Grunenthal GmbH, conducted this study, which J&JPRD has included as part of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol ER tablets for the management of moderate to severe chronic pain in patients 18 years of age or older. The FDA currently is reviewing this application and, if approved, PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will market tapentadol ER in the United States.

About tapentadolTapentadol is a centrally acting oral analgesic that binds to mu-opioid receptors and inhibits norepinephrine re-uptake. Although the exact mechanism of action is not known, these two mechanisms, which affect established pain pathways, are thought to be responsible for pain relief with tapentadol. The tapentadol molecule is classified as Schedule II of the Controlled Substances Act.

NUCYNTA® (tapentadol immediate release) was approved by the FDA on November 20, 2008, and is available by prescription only for the relief of moderate to severe acute pain in patients 18 years of age or older. On December 1, 2009, J&JPRD submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients 18 years of age or older [http://www.jnj.com/connect/news/product/20091201_200000]. The tapentadol ER tablet formulation is designed to provide a high degree of mecha
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
3. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
4. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
5. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
6. R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
7. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
8. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices
9. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
10. New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic
11. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and PITTSBURGH , Aug. ... ) today announced that its shareholders have approved ... PRGO ; TASE) and the related issuance ... an extraordinary general meeting of shareholders held today. ... cast at the extraordinary general meeting. In addition, ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
(Date:8/28/2015)... Massachusetts and LONDON , August ... approach seamlessly connects ... continuum improving outcomes and the ...  (NYSE: PHG AEX: PHIA) today announced its presence at  ... latest cardiology solutions, including Heart Model A.I. , EchoNavigator and ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that ... received preferred Tier 2 formulary status with all ... benefits manager, Prescription Solutions ® .  The AARP ... MedicareComplete from Secure Horizons, provide prescription drug access ...
... Omeros Corporation (NASDAQ: OMER ) ... its product candidates from its PharmacoSurgery™ platform – ... lens replacement surgery – into Phase 3 clinical ... added to standard irrigation solutions and delivered intra-operatively ...
Cached Medicine Technology:Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 4Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 5Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 6Omeros Announces Clinical Development Programs for OMS103HP and OMS302 2Omeros Announces Clinical Development Programs for OMS103HP and OMS302 3Omeros Announces Clinical Development Programs for OMS103HP and OMS302 4Omeros Announces Clinical Development Programs for OMS103HP and OMS302 5
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available on ... was required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations ... of the item’s selling price.” , With competitive pricing in the e-commerce market for ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
(Date:8/29/2015)... Houston, TX (PRWEB) , ... August 29, 2015 ... ... settlement allows the company to freely market and sell Arterosil and Arterosil HP, ... Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... by leading food management company ... 6 Pura Vida Coffee and leading food,service management ... the organizations announced at Pura Vida,s tenth,anniversary celebration in ... certified coffee, tea and,hot chocolate as official Fair Trade ...
... Small-Molecule Drugs for ... Spinal ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company focused on the ... today announced an expanded,research collaboration with the Spinal Muscular ...
... Dec. 6 OPKO Health, Inc. (Amex: OPK ... lead,compound for the treatment of wet age-related macular degeneration ... promising drugs entering Phase III,clinical trials during the third ... issue of The Ones to Watch report issued by ...
... Dec. 6 MyLongLife.com -- China is rushing ... the most ancient medical,systems on Earth embraces the ... MyLongLife.com., This dramatic thrust is being driven ... http://www.worldhealth.net/ ) reports,MyLongLife., It culminated ...
... HAYWARD, Calif., Dec. 6 Arete Therapeutics Inc., ... the treatment of cardiovascular, inflammatory and,metabolic diseases, today ... board of directors., "We are very pleased ... as his,strategic and operational insights will be of ...
... France, December 6 Essilor,has strengthened its prescription ... stakes in Sinclair Optical Services and United,Optical, two ... also acquired Premier Optics, Inc., Gold Optical Enterprises, ... Based in Gloucester, England, Sinclair Optical serves the ...
Cached Medicine News:Health News:Pura Vida Coffee and Compass Group Announce Strategic Partnership 2Health News:Pura Vida Coffee and Compass Group Announce Strategic Partnership 3Health News:PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation 2Health News:PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation 3Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 3Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 4Health News:China's Anti-Aging Revolution 2Health News:China's Anti-Aging Revolution 3Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Essilor Acquires Prescription Laboratories in the United Kingdom and the United States 2
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: